Intrinsically disordered proteins (IDPs) do not have a well-defined structure, but they have key biological tasks in cancer development. By using the disordered cancer-related protein NUPR1 as a proof-of-concept, we have developed a new multidisciplinary approach to tackle drug-design against IDPs, using it to repurpose drugs for treating pancreatic adenocarcinoma (PDAC).
Designing and repurposing drugs to target intrinsically disordered proteins for cancer treatment: using NUPR1 as a paradigm
Bruno Rizzuti;
2019
Abstract
Intrinsically disordered proteins (IDPs) do not have a well-defined structure, but they have key biological tasks in cancer development. By using the disordered cancer-related protein NUPR1 as a proof-of-concept, we have developed a new multidisciplinary approach to tackle drug-design against IDPs, using it to repurpose drugs for treating pancreatic adenocarcinoma (PDAC).File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Santofimia-Castaño et al., Mol Cell Oncol 2019;6,e1612678-1-3.pdf
accesso aperto
Descrizione: Santofimia-Castaño et al., Mol Cell Oncol 2019;6,e1612678-1-3
Tipologia:
Versione Editoriale (PDF)
Licenza:
Creative commons
Dimensione
1.71 MB
Formato
Adobe PDF
|
1.71 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
